Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose atropine eye drops (0.01%/0.02%) to slow myopia progression in children (Phase III, randomized, double-blind, placebo-controlled)
CTR20240786Phase 3Active
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Jun 2024
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atropine in myopia, sponsored by BrightGene Bio-Medical Technology. Started Jun 2024; status: active.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on CTR20240786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240786.